Next Article in Journal
CD163 Monoclonal Antibody Modified Polymer Prodrug Nanoparticles for Targeting Tumor-Associated Macrophages (TAMs) to Enhance Anti-Tumor Effects
Next Article in Special Issue
DNA Damage by Radiopharmaceuticals and Mechanisms of Cellular Repair
Previous Article in Journal
Chemical Constituents from the Roots of Angelica reflexa That Improve Glucose-Stimulated Insulin Secretion by Regulating Pancreatic β-Cell Metabolism
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 15
Issue 4
10.3390/pharmaceutics15041240
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals

by
Typhanie Ladrière
1,2,†,
Julie Faudemer
1,†,
Elise Levigoureux
3,4,
Damien Peyronnet
1,2,
Cédric Desmonts
1,5 and
Jonathan Vigne
1,2,6,*
1
Department of Nuclear Medicine, CHU de Caen Normandie, Normandie Université, UNICAEN, 14000 Caen, France
2
Department of Pharmacy, CHU de Caen Normandie, Normandie Université, UNICAEN, 14000 Caen, France
3
Hospices Civils de Lyon, Groupement Hospitalier Est, 69677 Bron, France
4
Lyon Neuroscience Research Center, CNRS UMR5292, INSERM U1028, Université Claude Bernard Lyon 1, 69677 Bron, France
5
INSERM U1086, ANTICIPE, Normandy University, UNICAEN, 14000 Caen, France
6
PhIND, Centre Cyceron, Institut Blood and Brain @ Caen-Normandie, INSERM U1237, Normandie Université, UNICAEN, 14000 Caen, France
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Pharmaceutics 2023, 15(4), 1240; https://doi.org/10.3390/pharmaceutics15041240
Submission received: 15 February 2023 / Revised: 24 March 2023 / Accepted: 7 April 2023 / Published: 13 April 2023
(This article belongs to the Special Issue Advances in the Development and Application of Targeted Radiopharmaceuticals for Cancer Management, 2nd Edition)
Browse Figures
Review Reports Versions Notes

Abstract

Peptide receptor radionuclide therapy (PRRT) using Lutetium-177 (177Lu) based radiopharmaceuticals has emerged as a therapeutic area in the field of nuclear medicine and oncology, allowing for personalized medicine. Since the first market authorization in 2018 of [¹⁷⁷Lu]Lu-DOTATATE (Lutathera®) targeting somatostatin receptor type 2 in the treatment of gastroenteropancreatic neuroendocrine tumors, intensive research has led to transfer innovative 177Lu containing pharmaceuticals to the clinic. Recently, a second market authorization in the field was obtained for [¹⁷⁷Lu]Lu-PSMA-617 (Pluvicto®) in the treatment of prostate cancer. The efficacy of 177Lu radiopharmaceuticals are now quite well-reported and data on the safety and management of patients are needed. This review will focus on several clinically tested and reported tailored approaches to enhance the risk–benefit trade-off of radioligand therapy. The aim is to help clinicians and nuclear medicine staff set up safe and optimized procedures using the approved 177Lu based radiopharmaceuticals.
Keywords: radiopharmaceuticals; Lutetium-177; nuclear medicine; peptide receptor radionuclide therapy; safety; dosimetry; risk management; nuclear medicine radiopharmaceuticals; Lutetium-177; nuclear medicine; peptide receptor radionuclide therapy; safety; dosimetry; risk management; nuclear medicine

Share and Cite

MDPI and ACS Style

Ladrière, T.; Faudemer, J.; Levigoureux, E.; Peyronnet, D.; Desmonts, C.; Vigne, J. Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals. Pharmaceutics 2023, 15, 1240. https://doi.org/10.3390/pharmaceutics15041240

AMA Style

Ladrière T, Faudemer J, Levigoureux E, Peyronnet D, Desmonts C, Vigne J. Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals. Pharmaceutics. 2023; 15(4):1240. https://doi.org/10.3390/pharmaceutics15041240

Chicago/Turabian Style

Ladrière, Typhanie, Julie Faudemer, Elise Levigoureux, Damien Peyronnet, Cédric Desmonts, and Jonathan Vigne. 2023. "Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals" Pharmaceutics 15, no. 4: 1240. https://doi.org/10.3390/pharmaceutics15041240

APA Style

Ladrière, T., Faudemer, J., Levigoureux, E., Peyronnet, D., Desmonts, C., & Vigne, J. (2023). Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals. Pharmaceutics, 15(4), 1240. https://doi.org/10.3390/pharmaceutics15041240

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop